tiprankstipranks

Clene initiated with a Buy at EF Hutton

EF Hutton initiated coverage of Clene with a Buy rating and $23 price target. Clene is a clinical stage biopharmaceutical company that develops novel therapeutic nanocatalysts for treating neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, the analyst tells investors in a research note. The firm says the company’s lead drug candidate CNM-Au8 appears to act at a cellular level on energy production in the central nervous system, noting that it takes 12 months to visualize results.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue